Metropolis Healthcare Ltd Share Price – NSE  /  BSE

Healthcare, Small Cap

Syngene International Ltd, Kaynes Technology India Ltd, Dr Lal Pathlabs Ltd, Sonata Software Ltd are among the other stocks to see a surge in volumes on BSE today, 12 April 2024.

Metropolis Healthcare Ltd recorded volume of 1.75 lakh shares by 10:47 IST on BSE, a 28.68 times surge over two-week average daily volume of 6094 shares. The stock gained 4.32% to Rs.1,877.05. Volumes stood at 16894 shares in the last session.

Syngene International Ltd witnessed volume of 64422 shares by 10:47 IST on BSE, a 9.95 times surge over two-week average daily volume of 6478 shares. The stock increased 3.69% to Rs.759.10. Volumes stood at 8475 shares in the last session.

Kaynes Technology India Ltd witnessed volume of 54134 shares by 10:47 IST on BSE, a 5.71 times surge over two-week average daily volume of 9477 shares. The stock dropped 0.93% to Rs.2,523.95. Volumes stood at 18627 shares in the last session.

Dr Lal Pathlabs Ltd clocked volume of 20066 shares by 10:47 IST on BSE, a 4.21 times surge over two-week average daily volume of 4765 shares. The stock gained 3.33% to Rs.2,381.80. Volumes stood at 6672 shares in the last session.

Sonata Software Ltd registered volume of 83486 shares by 10:47 IST on BSE, a 4.13 fold spurt over two-week average daily volume of 20239 shares. The stock slipped 0.68% to Rs.733.00. Volumes stood at 26391 shares in the last session.

Powered by Capital Market - Live News

During the period under review, the company’s revenue growth in core business was largely driven by volume growth, which stood at 8%.

The health care service provider reported 7% increased in RPP growth for Q4 FY24, was largely driven by growth in speciality tests segment, premium wellness segment and price increase.

Despite the prolonged holiday period, especially in March 2024, the company experienced around a 10% YoY increase in overall revenue, alongside mid-teen YoY growth in revenue for its core business, maintaining a consistent rise in sales volumes across various segments.

The company’s B2C revenues jumped 18% YoY in Q4FY24. Investments made in expanding the network, acquiring talent, upgrading information technology and refining processes are proving fruitful, as shown by the rise in sales volumes across both the B2C and B2B sectors.

EBIDTA Margins for Q4FY24 show a consistent upward trend both quarter-over-quarter and year-over-year. This boost in margin can be attributed mainly to the surge in volumes and implemented price increase.

During the current quarter, the company has repaid its debt, resulting in a debt-free status as of 31 March 2024.

“Competition intensity has been easing over the past 6 to 12 months, particularly as new industry entrants prioritize unit economics and profitability over deep discounting strategies. However, competition remains moderate in specific pockets of metropolitan markets, particularly within the B2B segment. Despite this competitive environment, the company has enhanced its market share in its core geographies and is successfully expanding its presence in newer territories with aggressive lab and network expansion strategy,” the company stated in the regulatory filing.

Metropolis Healthcare is a diagnostics company, with presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 192 labs, 4,127 collection centres and over 10,000 touch points.

Metropolis Healthcare reported 23.93% decline in consolidated net profit to Rs 27.28 crore in Q3 FY24 as compared with Rs 35.86 crore in Q3 FY23. Revenue from operations rose 1.98% YoY to Rs 391.11 crore in Q3 FY24.

The scrip hit 52 week high at Rs 1,935 in intraday today.

Powered by Capital Market - Live News

During the period under review, the company’s revenue growth in core business was largely driven by volume growth, which stood at 8%.

The health care service provider reported 7% increased in RPP growth for Q4 FY24, was largely driven by growth in speciality tests segment, premium wellness segment and price increase.

Despite the prolonged holiday period, especially in March 2024, the company experienced around a 10% YoY increase in overall revenue, alongside mid-teen YoY growth in revenue for its core business, maintaining a consistent rise in sales volumes across various segments.

The company’s B2C revenues jumped 18% YoY in Q4FY24. Investments made in expanding the network, acquiring talent, upgrading information technology and refining processes are proving fruitful, as shown by the rise in sales volumes across both the B2C and B2B sectors.

EBIDTA Margins for Q4FY24 show a consistent upward trend both quarter-over-quarter and year-over-year. This boost in margin can be attributed mainly to the surge in volumes and implemented price increase.

During the current quarter, the company has repaid its debt, resulting in a debt-free status as of 31 March 2024.

“Competition intensity has been easing over the past 6 to 12 months, particularly as new industry entrants prioritize unit economics and profitability over deep discounting strategies. However, competition remains moderate in specific pockets of metropolitan markets, particularly within the B2B segment. Despite this competitive environment, the company has enhanced its market share in its core geographies and is successfully expanding its presence in newer territories with aggressive lab and network expansion strategy,” the company stated in the regulatory filing.

Metropolis Healthcare is a diagnostics company, with presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 192 labs, 4,127 collection centres and over 10,000 touch points.

Metropolis Healthcare reported 23.93% decline in consolidated net profit to Rs 27.28 crore in Q3 FY24 as compared with Rs 35.86 crore in Q3 FY23. Revenue from operations rose 1.98% YoY to Rs 391.11 crore in Q3 FY24.

The scrip rose 1.77% to settle at Rs 1,799.35 on Wednesday, 10 April 2024.

The domestic market is closed today, on account of Ramadan Eid.

Powered by Capital Market - Live News

Revenue from operations rose 1.98% YoY to Rs 391.11 crore in Q3 FY24.

Profit before tax slipped 23.18% to Rs 36.85 crore in Q3 FY24 as compared with Rs 47.97 crore in Q3 FY23.

EBITDA (before CSR& ESOP) stood at Rs 69 crore, registering the de-growth of 10.39% as compared with Rs 77 crore posted in corresponding quarter last year. EBITDA margin was 23.6% in Q3 FY24 as against 27.1% in Q3 FY23.

During the quarter, Core Business revenue (excluding revenue from Covid & Covid Allied, PPP Contracts) stood at Rs 286 crore, up 12% YoY with 9% patient volume growth & 3% RPP growth.

Premium Wellness segments revenue grew by 15% & volumes grew by 11% indicating strong brand equity & consumer’s trust on Metropolis.

B2C revenue growth in Mumbai stood at 18% & volume growth of 13% on account of strong brand presence & dense network.

Ameera Shah, promoter and managing director, Metropolis Healthcare, said, “We continue to make positive strides in strengthening the business. Our strategic actions are yielding results and visible in our performance with B2C contribution of 53% and Specialized Tests contributing 38% of our core business revenues.

Looking ahead, our focus on the Metropolis 3.0 Strategy persists: expanding our network, strengthening doctor connections, fostering specialized and wellness segments, and upgrading IT infrastructure for an enhanced consumer experience.”

Surendran Chemmenkotil, CEO, Metropolis Healthcare, said, “The performance in Q3 was marginally impacted on account of heavy rainfall & floods in Chennai and adjacent areas in December 2023, leading to loss of revenues for approx. 7-8 days from Chennai region, which is one of the focus cities for Metropolis.”

Metropolis Healthcare is a diagnostics company, with presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 192 labs, 4,127 collection centres and over 10,000 touch points.

The scrip fell 0.13% to Rs 1612.10 on the BSE.

Powered by Capital Market - Live News